Update, 15 Nov: after this episode was recorded, Summit Therapeutics said the FDA had issued a complete response letter for ivonescimab, so it is not approved in the US for now. We'll cover it in Monday's weekly.
China's 2026 national reimbursement drug list adds 107 drugs, 51 of them Class 1 innovative, including the first CAR-T on the basic list, JW Therapeutics' (药明巨诺) relma-cel for lymphoma, from 1 January 2027. GLP-1 shots including Innovent's (信达生物) mazdutide are reimbursed for diabetes only; Novo Nordisk says China is the first country to reimburse its weekly insulin-semaglutide combination; Biokin's (百利天恒) iza-bren gets in for nasopharyngeal cancer; Akeso (康方生物) says ivonescimab was renewed at its original price. In the US, when we checked at 06:00 Singapore time Sunday, the FDA had not announced a decision on ivonescimab on its target day. Europe's CHMP backed two Chinese lung cancer drugs, Hansoh's (翰森制药) aumolertinib, seven weeks after the European Commission revoked its EU licence following a court challenge by AstraZeneca (the Commission acted before the court ruled), and Innovent's sintilimab. Plus China's new rules on blood and DNA samples leaving the country, and the US limits going the other way (our reading of the rules, not legal advice).
Full transcript and all sources for this episode
Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil holds no positions in any company mentioned.
Chapters
0:00 Intro and AI-voice disclosure
0:47 China's 2026 drug list: 107 new drugs
2:51 GLP-1s, Novo and iza-bren
5:34 Ivonescimab: no FDA word yet
6:41 Europe backs Hansoh and Innovent
8:42 The biosample border
11:08 What to watch and sign-off
Key sources: NHSA: 2026 National Reimbursement Drug List release (official) · China Daily: CAR-T enters China's basic medical insurance list for first time · EMA: CHMP meeting highlights, 9–12 November 2026 · Xinhua: China issues revised rules on management of human genetic resources
Weekly LinkedIn newsletter
Also listen on: Apple Podcasts · Amazon Music · YouTube